


**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof:



wherein:

R<sup>1</sup> represents aryl, heteroaryl, -aryl-X-C<sub>3-7</sub> cycloalkyl, -heteroaryl-X-C<sub>3-7</sub> cycloalkyl, -aryl-X-aryl, -aryl-X-heteroaryl, -aryl-X-heterocyclyl, -heteroaryl-X-heteroaryl, -heteroaryl-X-aryl or -heteroaryl-X-heterocyclyl;

wherein said aryl, heteroaryl and heterocyclyl groups of R<sup>1</sup> may be optionally substituted by one or more ~~(eg. 1, 2 or 3)~~ substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, haloC<sub>1-6</sub> alkyl, polyhaloC<sub>1-6</sub> alkyl, haloC<sub>1-6</sub> alkoxy, polyhaloC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkoxyC<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkylC<sub>1-6</sub> alkoxy, -COC<sub>1-6</sub> alkyl, -COC<sub>1-6</sub> alkyl-halogen, -COC<sub>1-6</sub> alkyl-cyano, C<sub>1-6</sub> alkoxycarbonyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyloxy, C<sub>1-6</sub> alkylsulfonylC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylsulfonamidoC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylamidoC<sub>1-6</sub> alkyl, aryl, arylsulfonyl, arylsulfonyloxy, aryloxy, arylsulfonamido, arylcarboxamido, aroyl, ~~or a group~~ NR<sup>15</sup>R<sup>16</sup>, -CONR<sup>15</sup>R<sup>16</sup>, -NR<sup>15</sup>COR<sup>16</sup>, -C(R<sup>15</sup>)=NOR<sup>16</sup>, -NR<sup>15</sup>SO<sub>2</sub>R<sup>16</sup> ~~or~~ and -SO<sub>2</sub>NR<sup>15</sup>R<sup>16</sup>, wherein R<sup>15</sup> and R<sup>16</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl or together form a heterocyclic ring;

X represents a bond, O, CO, SO<sub>2</sub>, OCH<sub>2</sub> or CH<sub>2</sub>O;

each R<sup>2</sup> and R<sup>4</sup> independently represents C<sub>1-4</sub> alkyl;

R<sup>3</sup> represents C<sub>3-8</sub> alkyl, C<sub>3-6</sub> alkenyl, C<sub>3-6</sub> alkynyl, C<sub>3-6</sub> cycloalkyl, C<sub>5-6</sub> cycloalkenyl or -C<sub>1-4</sub>alkyl-C<sub>3-6</sub> cycloalkyl;

wherein said C<sub>3-6</sub> cycloalkyl groups of R<sup>3</sup> may be optionally substituted by one or more ~~(eg. 1, 2 or 3)~~ substituents which may be the same or different, and which are selected from the group consisting of halogen, C<sub>1-4</sub> alkyl ~~or~~ and trifluoromethyl groups;

m and n independently represent 0, 1 or 2;

p and q independently represent 1 or 2;

~~or a pharmaceutically acceptable salt~~ solvate thereof.

2. (Original) A compound of formula (I) as defined in claim 1 wherein R<sup>1</sup> represents

-aryl optionally substituted by 1, 2 or 3 halogen, C<sub>1-6</sub> alkyl, polyhaloC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, polyhaloC<sub>1-6</sub> alkoxy, -COC<sub>1-6</sub> alkyl, -C(R<sup>15</sup>)=NOR<sup>16</sup>, -NR<sup>15</sup>COR<sup>16</sup>, -COC<sub>1-6</sub> alkyl-halogen, -COC<sub>1-6</sub> alkyl-cyano, cyano or C<sub>1-6</sub> alkoxycarbonyl groups;

-aryl-X-C<sub>3-7</sub> cycloalkyl;

-aryl-X-aryl;

-aryl-X-heterocyclyl optionally substituted by 1, 2 or 3 halogen or oxo groups;

-aryl-X-heteroaryl optionally substituted by a C<sub>1-6</sub> alkyl or aryl group;

-heterocyclyl optionally substituted by 1, 2 or 3 C<sub>1-6</sub> alkyl or -COC<sub>1-6</sub> alkyl groups;

heteroaryl optionally substituted by 1, 2 or 3 cyano, halogen, polyhaloC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkoxycarbonyl or -CONR<sup>15</sup>R<sup>16</sup> groups;

-heteroaryl-X-aryl optionally substituted by 1, 2 or 3 cyano or C<sub>1-6</sub> alkylsulfonyl groups;

-heteroaryl-X-heterocyclyl; or

-heteroaryl-X-heteroaryl.

3. (Original) A compound of formula (I) as defined in claim 2 wherein R<sup>1</sup> represents

phenyl, naphthyl or indanone optionally substituted by 1, 2 or 3 halogen, C<sub>1-6</sub> alkyl, polyhaloC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, polyhaloC<sub>1-6</sub> alkoxy, -COC<sub>1-6</sub> alkyl, -C(R<sup>15</sup>)=NOR<sup>16</sup>, -NR<sup>15</sup>COR<sup>16</sup>, -COC<sub>1-6</sub> alkyl-halogen, -COC<sub>1-6</sub> alkyl-cyano, cyano or C<sub>1-6</sub> alkoxycarbonyl groups;

-phenyl-CO-cyclopropyl or -phenyl-CO-cyclobutyl;

-phenyl-thiazolyl, -phenyl-oxadiazolyl, -phenyl-pyrrolyl, -phenyl-oxazolyl or -phenyl-isoxazolyl optionally substituted by a C<sub>1-6</sub> alkyl or aryl group; or

pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, quinolinyl, isoquinolinyl or benzothiazolyl optionally substituted by 1, 2 or 3 cyano, halogen, polyhaloC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkoxycarbonyl or -CONR<sup>15</sup>R<sup>16</sup> groups.

4. (Original) A compound of formula (I) as defined in claim 3 wherein R<sup>1</sup> represents

phenyl optionally substituted by 1, 2 or 3 halogen, polyhaloC<sub>1-6</sub> alkyl, -NR<sup>15</sup>COR<sup>16</sup>, -COC<sub>1-6</sub> alkyl or cyano groups;

-phenyl-CO-cyclopropyl;

-phenyl-oxadiazolyl or -phenyl-oxazolyl optionally substituted by a C<sub>1-6</sub> alkyl or aryl group; or

pyridyl, pyrimidyl, pyrazinyl, pyridazinyl or quinolinyl optionally substituted by 1, 2 or 3 halogen, polyhaloC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyl or cyano groups.

5. (Original) A compound of formula (I) as defined in claim 4 wherein R<sup>1</sup> represents

phenyl optionally substituted at the 4-position by a -COMe, -COEt or cyano group; or  
pyridyl or quinolinyl optionally substituted by a methyl or CF<sub>3</sub> group.

6. (Original) A compound of formula (I) as defined in claim 5 wherein R<sup>1</sup> represents  
- 6-CF<sub>3</sub>-pyridin-3-yl.

7. (Currently Amended) A compound of formula (I) as defined in ~~any one of claims 1 to 6~~ claim 1 wherein X represents a bond, O or CO.

8. (Original) A compound of formula (I) as defined in claim 7, wherein X represents a bond or CO.

9. (Currently Amended) A compound of formula (I) as defined in ~~any one of claims 1 to 8~~ claim 1 wherein m represents 0.

10. (Currently Amended) A compound of formula (I) as defined in ~~any one of claims 1 to 9~~ claim 1 wherein n represents 0, 1 or 2.

11. (Original) A compound of formula (I) as defined in claim 10 wherein n represents 0 or 1.

12. (Currently Amended) A compound of formula (I) as defined in claim 10 ~~or claim 11~~ wherein R<sup>2</sup> represents methyl.

13. (Original) A compound of formula (I) as defined in claim 11 wherein n represents 0.

14. (Currently Amended) A compound of formula (I) as defined in ~~any one of claims 1 to 13~~ claim 1 wherein q represents 1.

15. (Currently Amended) A compound of formula (I) as defined in ~~any one of claims 1 to 14~~ claim 1 wherein R<sup>3</sup> represents C<sub>3-8</sub> alkyl or C<sub>3-6</sub> cycloalkyl.

16. (Original) A compound of formula (I) as defined in claim 15 wherein R<sup>3</sup> represents isopropyl, isobutyl or cyclobutyl.

17. (Original) A compound of formula (I) as defined in claim 16 wherein R<sup>3</sup> represents isopropyl or cyclobutyl.

18. (Original) A compound of formula (I) as defined in claim 17 wherein R<sup>3</sup> represents isopropyl.

19. (Currently Amended) A compound of formula (I) as defined in claim 1 which is a compound of E1-E198 or a pharmaceutically acceptable salt or solvate thereof.

20. (Currently Amended) A compound of formula (I) as defined in claim 1 which is 1-Isopropyl-4-[1-(5-cyano-pyridin-2-yl)-piperidine-4-carbonyl]-piperazine;  
1-Isopropyl-4-[1-(5-methoxycarbonyl-4-trifluoromethylpyridin-2-yl)-piperidine-4-carbonyl]-piperazine;  
1-Isopropyl-4-[1-(4-ethoxycarbonylphenyl)-piperidine-4-carbonyl]-piperazine;  
1-Cyclobutyl-4-[1-(4-cyanophenyl)-piperidine-4-carbonyl]-piperazine;  
1-Cyclobutyl-4-[1-(4-cyano-3-fluorophenyl)-piperidine-4-carbonyl]-piperazine;  
1-Cyclobutyl-4-[1-(4-cyano-2,6-difluorophenyl)-piperidine-4-carbonyl]-piperazine;  
1-Cyclobutyl-4-[1-(4-cyano-3-trifluoromethylphenyl)-piperidine-4-carbonyl]-piperazine;  
1-Cyclobutyl-4-[1-(4-cyano-naphthalen-1-yl)-piperidine-4-carbonyl]-piperazine;  
1-Cyclobutyl-4-[1-(5-cyanopyridin-2-yl)-piperidine-4-carbonyl]-piperazine;  
1-Cyclobutyl-4-[1-(6-trifluoromethylpyridin-2-yl)-piperidine-4-carbonyl]-piperazine;  
1-Cyclobutyl-4-[1-(5-trifluoromethylpyridin-2-yl)-piperidine-4-carbonyl]-piperazine;  
1-Cyclobutyl-4-[1-(3-chloro-5-trifluoromethylpyridin-2-yl)-piperidine-4-carbonyl]-piperazine;  
1-Isopropyl-4-[1-[5-(4-methylsulfonylphenyl)-pyrimidin-2-yl]-piperidine-4-carbonyl]-piperazine;  
1-Isopropyl-4-[1-[4-(morpholino-carbonyl)-phenyl]-piperidine-4-carbonyl]-piperazine;  
1-Cyclopentyl-4-[1-(4-cyano-phenyl)-piperidine-4-carbonyl]-piperazine;  
(2*R*,6*S*)-1-Cyclobutyl-4-[1-(4-cyanophenyl)-piperidine-4-carbonyl]-2,6-dimethylpiperazine;  
1-Isopentyl-4-[1-(5-cyano-pyridin-2-yl)-piperidine-4-carbonyl]-piperazine;  
1-Cyclobutyl-4-[1-(4-cyanophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Cyclobutyl-4-[1-(5-cyanopyridin-2-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(4-cyano-2,5-difluorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(4-cyano-3-chlorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(4-cyano-3-fluoro-phenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(4-cyano-2,6-difluoro-phenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;

1-Isopropyl-4-[1-(4-cyano-2-fluoro-phenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(4-cyano-3-trifluoromethyl-phenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(4-trifluoromethyl-phenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(4-cyano-naphthalen-1-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(3,4-dichlorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(4-trifluoromethoxyphenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(4-difluoromethoxyphenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(4-phenoxyphenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(6-methoxypyridin-3-yl)-piperidine-4-carbonyl]-[1,4]-diazepane; 1-Isopropyl-4-[1-(4-cyano-2,3-difluorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(4-cyano-2-chlorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Cyclobutyl-4-[1-(4-cyano-2-chlorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Cyclobutyl-4-[1-(4-cyano-3-chlorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Cyclobutyl-4-[1-(4-cyano-3-fluorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Cyclobutyl-4-[1-(4-cyano-3-trifluoromethylphenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Cyclobutyl-4-[1-(4-cyano-2,5-difluorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
(S)-1-Isopropyl-4-[1-(4-cyanophenyl)-piperidine-4-carbonyl]-2-methylpiperazine;  
(S)-1-Isopropyl-4-[1-(6-cyanopyridin-3-yl)-piperidine-4-carbonyl]-2-methylpiperazine;  
(S)-1-Isopropyl-4-[1-(5-cyanopyridin-2-yl)-piperidine-4-carbonyl]-2-methylpiperazine;  
(S)-1-Isopropyl-4-[1-(5-trifluoromethyl-pyrazin-2-yl)-piperidine-4-carbonyl]-2-methyl piperazine;  
(S)-1-Isopropyl-4-[1-(6-trifluoromethyl-pyridazin-3-yl)-piperidine-4-carbonyl]-2-methyl piperazine;  
1-Isopropyl-4-{1-[4-(5-phenyl-1,3,4-oxadiazol-2-yl)phenyl]-piperidine-4-carbonyl} piperazine;  
1-Isopropyl-4-[1-(quinolin-6-yl)-piperidine-4-carbonyl] piperazine;

1-Cyclobutyl-4-[1-(6-trifluoromethylpyridin-3-yl)-piperidine-4-carbonyl]piperazine;  
1-Isopropyl-4-[1-(5-trifluoromethyl-pyrazin-2-yl)-piperidine-4-carbonyl]piperazine;  
(S)-1-Isobutyl-4-[1-(4-cyanophenyl)-piperidine-4-carbonyl]-piperazine;  
1-Isopropyl-4-[1-(4-cyclopropylcarbonylphenyl)-piperidine-4-carbonyl]piperazine;  
1-Isopropyl-4-[1-(2-methyl-quinolin-6-yl)-piperidine-4-carbonyl]-piperazine;  
1-Isopropyl-4-[1-(6-cyano-pyridin-3-yl)-piperidine-4-carbonyl]-piperazine;  
1-Cyclobutyl-4-[1-(6-trifluoromethylpyridin-3-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Cyclobutyl-4-[1-(2-cyanopyridin-4-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(6-trifluoromethylpyridazin-3-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(5-trifluoromethylpyrazin-2-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-[4-(2-methyl-1,3-oxazol-5-yl)phenyl]-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(4-acetamido-3-fluorophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Cyclobutyl-4-[1-(4-acetylphenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Cyclobutyl-4-[1-(6-cyano-pyridin-3-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(6-cyano-pyridin-3-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(2-methyl-quinolin-4-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-piperidine-4-carbonyl]-piperazine;  
1-Isopropyl-4-[1-(2-trifluoromethylpyrimidin-5-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
or a pharmaceutically acceptable salt or solvate thereof.

21. (Currently Amended) A compound of formula (I) as defined in claim 1 which is

1-Isopropyl-4-[1-(4-cyanophenyl)-piperidine-4-carbonyl]-piperazine;  
1-Isopropyl-4-[1-(4-cyanophenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
(S)-1-Isopropyl-4-[1-(6-trifluoromethylpyridin-3-yl)-piperidine-4-carbonyl]-2-methyl piperazine;  
1-Isopropyl-4-[1-(4-acetylphenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
1-Isopropyl-4-[1-(4-propanoylphenyl)-piperidine-4-carbonyl]-[1,4]-diazepane;  
or a pharmaceutically acceptable salt or solvate thereof.

22. (Currently Amended) A compound of formula (I) as defined in claim 1 which is

1-Isopropyl-4-[1-(6-trifluoromethylpyridin-3-yl)-piperidine-4-carbonyl]-piperazine;

1-Isopropyl-4-[1-(6-trifluoromethylpyridin-3-yl)-piperidine-4-carbonyl]-[1,4]-diazepane;

or a pharmaceutically acceptable salt or solvate thereof.

23. (Currently Amended) A pharmaceutical composition which comprises the compound of formula (I) as defined in ~~any one of claims 1 to 22~~ claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

24. (Cancelled)

25. (Cancelled)


26. (Cancelled)

27. (Currently Amended) A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in ~~any one of claims 1 to 22~~ claim 1 or a pharmaceutically acceptable salt thereof.

28. (Cancelled)

29. (Original) A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting a compound of formula (II)




(II)


or an optionally activated or protected derivative thereof, wherein  $R^2$ ,  $R^4$ ,  $m$ ,  $n$ ,  $p$  and  $q$  are as defined in claim 1 and  $R^{3a}$  is as defined for  $R^3$  in claim 1 or a group convertible to  $R^3$ , with a compound of formula  $R^1-L^1$ , wherein  $R^1$  is as defined in claim

1 and  $L^1$  represents a suitable leaving group, such as a halogen atom followed by a deprotection reaction as necessary; or

(b) reacting a compound of formula (III)



wherein  $R^1$ ,  $R^4$ ,  $m$  and  $q$  are as defined in claim 1 and  $L^2$  represents OH or a suitable leaving group, such as a halogen atom, with a compound of formula (IV)



wherein  $R^2$ ,  $n$  and  $p$  are as defined in claim 1  $R^{3a}$  is as defined for  $R^3$  in claim 1 or a group convertible to  $R^3$ ; or

(c) deprotecting a compound of formula (I) or converting groups which are protected; and optionally thereafter

(d) interconversion to other compounds of formula (I).